Aptorum Group (Aptorum Group) Change In Receivables : $0.41 Mil (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Change In Receivables?

Aptorum Group's change in receivables for the quarter that ended in Jun. 2023 was $0.09 Mil. It means Aptorum Group's Accounts Receivable declined by $0.09 Mil from Dec. 2022 to Jun. 2023 .

Aptorum Group's change in receivables for the fiscal year that ended in Dec. 2022 was $-0.17 Mil. It means Aptorum Group's Accounts Receivable increased by $0.17 Mil from Dec. 2021 to Dec. 2022 .

Aptorum Group's Accounts Receivable for the quarter that ended in Jun. 2023 was $0.07 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Aptorum Group's Days Sales Outstanding for the six months ended in Jun. 2023 was 27.95.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Aptorum Group's liquidation value for the six months ended in Jun. 2023 was $-1.24 Mil.

Aptorum Group Change In Receivables Historical Data

The historical data trend for Aptorum Group's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Change In Receivables Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-0.13

0.21

-0.17

0.88

-0.17

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial							0.52	0.36	-0.49	0.32	0.09

Aptorum Group Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.41 Mil.

Aptorum Group (NAS:APM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Aptorum Group's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.066	/	0.431	*	91
=	27.95

2. In Ben Graham's calculation of liquidation value, Aptorum Group's accounts receivable are only considered to be worth 75% of book value:

Aptorum Group's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.34	-	1.633	+	0.75 * 0.066	+	0.5 * 0
=	-1.24

Aptorum Group Change In Receivables Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptorum Group (Aptorum Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.